Qinecsa
Qinecsa is a pharmacovigilance and drug safety services provider that supports pharmaceutical and biotech companies with end‑to‑end safety operations, including case processing, signal management, medical review, and regulatory reporting. It combines specialized safety operations teams with proprietary technology platforms to help clients manage global safety data and comply with regulatory requirements across the product lifecycle. The company generates revenue through outsourced safety services and technology-enabled safety solutions delivered on a contract basis.
- IT Consulting & Implementation
- Revenue
- $120.0M
- Employees
- 900
- Founded
- 2021
- Headquarters
- Londonderry County Borough, United Kingdom
What 9 Arbolus experts think of Qinecsa
NPS scores for Qinecsa are weighted toward promoters, with over 70% sharing scores of 8 or above; a minority are neutral or unsure. 60% of experts express explicit renewal intent while others remain open or cautious, especially those piloting the platform. Stickiness is highest among mid- to large-sized enterprises and organizations with expansive compliance needs. Key positive themes are regulatory expertise, reliability, and operational efficiency, while caution centers on advanced AI features and global scalability. Overall Customer Sentiment: Positive
Who reviewed Qinecsa
- C-Suite 33% (3)
- Director 56% (5)
- Manager 11% (1)
Employer names and spend open in the full report, along with the other 6 customers.
Everything 9 customers told us about Qinecsa.
Employer names, spend, renewal intent and every written answer behind the numbers on this page.
Sentiment
11 Net Promoter Score, from 9 scored reviews- Promoters 3
- Passives 4
- Detractors 2
Cumulative NPS by month
+2 over 5 months- Jan 5
- Apr 7
- Jun 8
- Jul 7
- Aug 7
Net Promoter Score across 3 reviews, accumulated up to each month. Category median 25 across 3 companies.
Praised
- Modernized User Experience
- AI Automation for End-to-End Workflows
- Growth in Compliance-Focused Segments
- Specialized Regulatory and PV Expertise
Criticised
- UI and Customization Gaps
- Limited Advanced AI Integration
- Scalability for Large Pharma
- Compliance or Quality Failures
What customers say
Renewal intent
Plan to renew 56%Plan to renew, by seniority
- 33% 3 answers
- 80% 5 answers
- 0% 1 answer
- 8.8/10 Average score from customers who will renew
- 6.3/10 Average score from undecided customers
- 0/10 Average score from customers not renewing
Top alternatives
Most weighed by Qinecsa customers
Report
More in Data & Analytics
Other companies in Data & Analytics with a customer report.
For people who use Qinecsa
Do you use Qinecsa at work?
Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.
- 9 customers of Qinecsa have already contributed
Takes a few minutes. Your identity stays anonymous.